October 8, 2024

HHSC TO REMOVE OXBRYTA PRODUCTS FROM ALL FORMULARIES AS OF OCT. 10, 2024

BACKGROUND

On Sept. 25, 2024, Pfizer, the manufacturer of Oxbryta, announced a voluntary withdrawal of all Oxbryta (voxelotor) products from worldwide markets. On Sept. 26, 2024, the FDA followed with an announcement alerting patients and healthcare professionals about the voluntary withdrawal of Oxbryta due to safety concerns.

KEY DETAILS

HHSC will remove the following Oxbryta products and their clinical prior authorization from all formularies as of Oct. 10, 2024. MCOs must remove these NDCs from their system by Oct. 10, 2024.

NDC	Drug Name
72786010101	OXBRYTA 500 MG TABLET
72786011102	OXBRYTA 300 MG TABLET FOR SUSP
72786011103	OXBRYTA 300 MG TABLET FOR SUSP
72786010202	OXBRYTA 300 MG TABLET
72786010203	OXBRYTA 300 MG TABLET